Les projets que nous finançons (uniquement en anglais)

Funded projects
Men's Health Partners
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP3 Prostate Cancer Active Surveillance

Movember Funding to Date

Global Fund of AUD 5,920,449

What we seek to achieve

By integrating pathology, clinical, imaging and biomarker data into a global central database, GAP3 has united the world's leading research and clinical groups focusing on prostate cancer Active Surveillance, with the aim to help facilitate treatment decision making for clinicians and men diagnosed with low risk prostate cancer.

United States
Implemented by
The Movember Foundation
Project start date
August 2013
Project Status
In Progress

About the project

Men that are newly diagnosed with low risk prostate cancer are often given the possibility to choose between active treatment (surgery, radiation therapy) or active surveillance (monitoring of the disease without active treatment). By choosing active surveillance, men will avoid (or at least defer) secondary side-effects associated with active treatment, such as urinary, bowel and erectile dysfunction. The objective of GAP3 is to better understand which men are the best candidates for Active Surveillance and which should receive active treatment.

In order to do this:

  • Patient data from Active Surveillance protocols, including clinical and Patient Reported Outcome Measures, from around the world will be uploaded to a central global database.
  • Statisticians, epidemiologists and clinicians will use the data in the central global database to determine the optimal way to monitor (or treat) men with low risk Prostate Cancer.
  • The findings of the research will help facilitate treatment decision making for clinicians and men with low risk disease.
  • Links between GAP1 (Biomarkers) and GAP2 (Imaging) will be leveraged, and continual review of synergies with other Movember projects.
This project is governed by the GAP3 Project Research Advisory Committee. This global committee of highly regarded experts in the field have guided and shaped the project in conjunction with the GAP3 Project Leaders around the world.

Page 1 of 29